Do You Understand Every Impurity?

Follow the step-by step the pathway to develop your biotherapeutic peptide

From impurity characterization to regulatory compliance, explore how robust LC and LC-MS workflows help bring biotherapeutic peptides to market faster while ensuring product quality and safety.

Join our webinar series which addresses each stage and hear expert discussions on how analytical solutions can help accelerate time to market and speed up regulatory approvals.

Step 3: Do You Understand Every Impurity?

Impurity and Variant Characterization

Regulators are placing greater emphasis on understanding peptide-related impurities and degradation products. Variants such as oxidation, deamidation, truncations, insertions, epimerization, and aggregation can impact safety, efficacy, and immunogenicity.

Learn how orthogonal analytical approaches can provide a comprehensive understanding of your impurity profile and support regulatory expectations for peptide therapeutics.

GLP-1 receptor agonist manufacturers need to assess your GLP-1 product for purity, and critical quality attributes as impurities can affect safety, efficacy and immunogenicity.

Why attend?

• Characterize critical peptide-related impurities and variants
• Identify low-level degradants with greater confidence
• Understand evolving regulatory expectations for impurity control
• Explore multi-attribute analytical strategies for peptide characterization

Key takeaway

Learn how to identify, characterize, and justify impurities before they become regulatory obstacles.

Meet the Expert(s)

Hear from Waters scientists and market experts who work with pharmaceutical manufacturers every day to solve analytical challenges across the entire GLP-1 development lifecycle, from molecule characterization and purification through to QC and regulatory readiness.

Speaker: Pawel Bigos (Senior Scientist, Waters Corporation)

Pawel Bigos is a Senior Scientist at Waters Corporation in the QA/QC Biologics group in Milford, Massachusetts. He holds a Bachelor of Science degree in Chemistry from the University of South Florida.

Prior to Waters, Pawel gained valuable experience at Frequency Therapeutics, Novartis, and Symbiotic Research. Since joining Waters in 2022, he has concentrated on biomolecule separations and plays a critical role in providing analytical support in the development, commercialization, and application of Waters innovative products.

Speaker: Antonia Wierzbicki (Principal MS Market Development Manager, EMEA, Waters Corporation)

Antonia Wierzbicki is Principal Market Development Manager for Pharma in EMEA at Waters Corporation. She leads strategic initiatives focused on therapeutic peptides, GLP-1 receptor agonists, DMPK, and bioanalysis. Working closely with pharmaceutical innovators, CDMOs, and peptide manufacturers, Antonia helps organizations address analytical challenges throughout development and manufacturing. In this session, she will explore purification strategies that enable improved impurity control, greater analytical confidence, and faster GLP-1 development.